According to the 2017 European LeukemiaNet (ELN) risk stratification, all ‘AML with CBFB-MYH11’ patients in our cohort are considered favourable, whereas ‘primary AML with MRC’ patients have either intermediate or adverse risk37. The gene discussed is MYH11; the disease is acute myeloid leukemia.